Skip to main content

Table 1 Patient characteristics according to sTIL categories. sTIL categories were defined as “low sTILs” (0–10% sTILs), “intermediate sTILs” (11–50% sTILs), and “high sTILs” (51–100% sTILs)

From: Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

  All Low sTILs (valid %) Intermediate sTILs (valid %) High sTILs (valid %) p value, chi-square
Tumor stage
pT1 1499 1232 (82.2) 218 (14.5) 49 (3.3) .760
pT22 1088 885 (81.5) 163 (15.0) 38 (3.5)  
pT3 89 75 (84.3) 13 (14.6) 1 (1.1)  
pT4 17 16 (94.1) 1 (5.9) 0 (0.0)  
Nodal status
pN0 1843 1499 (81.3) 274 (14.9) 70 (3.8) .021
pN1 978 829 (84.8) 130 (13.3) 19 (1.9)  
pN2–3 172 143 (831) 27 (15.7) 2 (1.2)  
ER (local)
Negative 445 256(57.5) 143 (32.1) 46 (10.3) < .001
Positive 2246 1952 (86.9) 252 (11.2) 42 (1.9)  
PR local
Negative 625 399 (63.8) 172 (27.5) 54 (8.6) < .001
Positive 2066 1809 (87.6) 223 (10.8) 34 (1.6)  
Local HR status
Negative 419 236 (56.3) 138 (32.9) 45 (10.7) < .001
Positive 2574 2235 (86.8) 293 (11.4) 46 (1.8)  
Age at registration
≤ 50 984 794 (80.7) 163 (16, 6) 27 (2.7) .055
> 50 2009 1677 (83.5) 268 (13.3) 64 (3.2)  
Ki67 expression
1–15 1040 959 (92.2) 76 (7.3) 5 (0.5) < .001
15–34 1383 1113 (80.5) 223 (16.1) 47 (3.4)  
35–100 305 159 (52.1) 112 (36.7) 34 (11.1)  
Recurrence Score
Low (0–11) 449 423 (94.2) 25 (5.6) 1 (0.2) < .001
Intermediate (12–25) 1509 1345 (89.1) 146 (9.7) 18 (1.2)  
High (26–99) 546 407 (74.5) 112 (20.5) 27 (4.9)